SCHEMBL223760

SCHEMBL223760

[c]1c2c(nc3ccccc13)CNC2

nearest known ligand 0.31

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.30
BCHE P06276 2/20 0.30
ACHE P22303 2/20 0.30
KDM4E B2RXH2 1/20 0.30
CACNB4 O00305 1/20 0.30
CACNA1A O00555 1/20 0.30
SLC22A2 O15244 1/20 0.30
SLC22A1 O15245 1/20 0.30
ABCC4 O15439 1/20 0.30
CACNA1G O43497 1/20 0.30
CACNG3 O60359 1/20 0.30
CACNA1F O60840 1/20 0.30
CACNA1H O95180 1/20 0.30
ALDH1A1 P00352 1/20 0.30
APP P05067 1/20 0.30
CYP1A2 P05177 1/20 0.30
FABP1 P07148 1/20 0.30
CHRM2 P08172 1/20 0.30
CYP3A4 P08684 1/20 0.30
ADRA2A P08913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222039 0.85 PARP1 (0.37) BCHEACHEKDM4ECACNB4CACNA1A
SCHEMBL223109 0.85 MAPT (0.36) BCHEACHEKDM4ECACNB4CACNA1A
SCHEMBL4909847 0.73 BCHE (0.45) BCHEACHEKDM4ECACNB4CACNA1A
SCHEMBL1532144 0.73 BCHE (0.45) BCHEACHEKDM4ECACNB4CACNA1A
SCHEMBL4464318 0.71 BCHE (0.46) BCHEACHEKDM4ECACNB4CACNA1A
SCHEMBL23981 0.69 MAPT (0.56) TDP1ACHEKDM4EALDH1A1CHRM2
SCHEMBL9169062 0.63 ACHE (0.58) TDP1BCHEACHEKDM4ECACNB4
SCHEMBL5550904 0.63 ALDH1A1 (0.46) TDP1ACHEKDM4EALDH1A1CYP1A2
SCHEMBL6312249 0.62 HTR2C (0.47) CYP3A4MAPT
SCHEMBL11198754 0.61 KDM4E (0.43) BCHEACHEKDM4ECACNB4CACNA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641761-A4 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS MERCK & CO INC (US) 2008-05-14 EP claimed
US-20070088028-A1 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators MERCK & CO., INC. 2007-04-19 US claimed
EP-1641761-A2 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2006-04-05 EP claimed
WO-2005004807-A2 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2005-01-20 WO claimed
WO-2024150222-A1 IONIZABLE LIPIDS AND NANOPARTICLES COMPRISING SAME MANA BIO LTD. (IL) 2024-07-18 WO disclosed
EP-4376837-A1 COMPOUNDS FOR NEUTROPHIL ROS INHIBITION Immunyx Pharma Ltd. (IL) 2024-06-05 EP disclosed
US-20240156742-A1 TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-05-16 US disclosed
US-20240148886-A1 INTRACELLULAR DELIVERY COMPOSITIONS BIOND BIOLOGICS LTD. (IL) 2024-05-09 US disclosed
WO-2024069634-A1 MICROTUBULE TARGETING AGENTS Ariel Scientific Innovations Ltd. (IL) 2024-04-04 WO disclosed
WO-2024052923-A1 IONIZABLE LIPIDS AND COMPOSITIONS COMPRISING SAME BARCODE NANOTECH LTD. (IL) 2024-03-14 WO disclosed
EP-4326332-A1 INTRACELLULAR DELIVERY COMPOSITIONS Biond Biologics Ltd. (IL) 2024-02-28 EP disclosed
WO-2024033917-A1 GRANULAR COMPOSITIONS COMPRISING A PEPTIDE AND USES THEREOF TARSIER PHARMA LTD. (IL) 2024-02-15 WO disclosed
US-20070219395-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-20 US disclosed
US-7238835-B2 Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-07-03 US disclosed
US-20070088028-A1 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators MERCK & CO., INC. 2007-04-19 US disclosed
EP-1699748-A2 METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS Sanofi-Aventis Deutschland GmbH (DE) 2006-09-13 EP disclosed
EP-1641761-A2 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2006-04-05 EP disclosed
US-20050171205-A1 Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-08-04 US disclosed
WO-2005061427-A2 METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-07-07 WO disclosed
WO-2005004807-A2 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219395-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS CYP2B6, CYP1B1, CYP4B1 TDP1 3423/4885BCHE 1657/4885ACHE 3862/4885
US-20240156742-A1 TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS LCAT, CD47, PHOSPHO1 TDP1 4530/4885BCHE 2302/4885ACHE 3133/4885
US-20240148886-A1 INTRACELLULAR DELIVERY COMPOSITIONS ACTB, CHERP, EEA1 TDP1 3385/4885BCHE 3111/4885ACHE 4801/4885
US-20050171205-A1 Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids CYP2B6, CYP1B1, CYP4B1 TDP1 3423/4885BCHE 1657/4885ACHE 3862/4885
US-20070088028-A1 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators AR, SHBG, NR5A1 TDP1 418/4885BCHE 2001/4885ACHE 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.